81 related articles for article (PubMed ID: 19117759)
1. New quinoline NK3 receptor antagonists with CNS activity.
Smith PW; Wyman PA; Lovell P; Goodacre C; Serafinowska HT; Vong A; Harrington F; Flynn S; Bradley DM; Porter R; Coggon S; Murkitt G; Searle K; Thomas DR; Watson JM; Martin W; Wu Z; Dawson LA
Bioorg Med Chem Lett; 2009 Feb; 19(3):837-40. PubMed ID: 19117759
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics.
Dawson LA; Langmead CJ; Dada A; Watson JM; Wu Z; de la Flor R; Jones GA; Cluderay JE; Southam E; Murkitt GS; Hill MD; Jones DN; Davies CH; Hagan JJ; Smith PW
Eur J Pharmacol; 2010 Feb; 627(1-3):106-14. PubMed ID: 19879867
[TBL] [Abstract][Full Text] [Related]
3. Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.
Sarau HM; Griswold DE; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Webb EF; Martin LD; Legos JJ; Whitmore RG; Barone FC; Medhurst AD; Luttmann MA; Giardina GA; Hay DW
J Pharmacol Exp Ther; 2000 Oct; 295(1):373-81. PubMed ID: 10992004
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of antipsychotic-induced neurochemical changes by the NK3 receptor antagonist talnetant (SB-223412).
de la Flor R; Dawson LA
Neuropharmacology; 2009 Feb; 56(2):342-9. PubMed ID: 18822303
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).
Giardina GA; Raveglia LF; Grugni M; Sarau HM; Farina C; Medhurst AD; Graziani D; Schmidt DB; Rigolio R; Luttmann M; Cavagnera S; Foley JJ; Vecchietti V; Hay DW
J Med Chem; 1999 Mar; 42(6):1053-65. PubMed ID: 10090788
[TBL] [Abstract][Full Text] [Related]
6. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia.
Dawson LA; Cato KJ; Scott C; Watson JM; Wood MD; Foxton R; de la Flor R; Jones GA; Kew JN; Cluderay JE; Southam E; Murkitt GS; Gartlon J; Pemberton DJ; Jones DN; Davies CH; Hagan J
Neuropsychopharmacology; 2008 Jun; 33(7):1642-52. PubMed ID: 17728699
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and SAR of sulfoxide substituted carboxyquinolines as NK3 receptor antagonists.
Xiong H; Kang J; Woods JM; McCauley JP; Koether GM; Albert JS; Hinkley L; Li Y; Gadient RA; Simpson TR
Bioorg Med Chem Lett; 2011 Mar; 21(6):1896-9. PubMed ID: 21320776
[TBL] [Abstract][Full Text] [Related]
9. Localization and function of NK(3) subtype tachykinin receptors of layer V pyramidal neurons of the guinea-pig medial prefrontal cortex.
Simmons MA; Sobotka-Briner CD; Medd AM
Neuroscience; 2008 Oct; 156(4):987-94. PubMed ID: 18801417
[TBL] [Abstract][Full Text] [Related]
10. Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor.
Geldenhuys WJ; Kuzenko SR; Simmons MA
J Med Chem; 2010 Nov; 53(22):8080-8. PubMed ID: 21047106
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potent, balanced and orally active dual NK1/NK3 receptor ligands.
Peters JU; Hoffmann T; Schnider P; Stadler H; Koblet A; Alker A; Poli SM; Ballard TM; Spooren W; Steward L; Sleight AJ
Bioorg Med Chem Lett; 2010 Jun; 20(11):3405-8. PubMed ID: 20430616
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of 2-(4-biphenylyl)quinoline-4-carboxylate and carboxamide analogs. New human neurokinin-3 (hNK-3) receptor antagonists.
Saudi MN; Rostom SA; Fahmy HT; El Ashmawy IM
Arch Pharm (Weinheim); 2003 Jun; 336(3):165-74. PubMed ID: 12822182
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.
Reavill C; Taylor SG; Wood MD; Ashmeade T; Austin NE; Avenell KY; Boyfield I; Branch CL; Cilia J; Coldwell MC; Hadley MS; Hunter AJ; Jeffrey P; Jewitt F; Johnson CN; Jones DN; Medhurst AD; Middlemiss DN; Nash DJ; Riley GJ; Routledge C; Stemp G; Thewlis KM; Trail B; Vong AK; Hagan JJ
J Pharmacol Exp Ther; 2000 Sep; 294(3):1154-65. PubMed ID: 10945872
[TBL] [Abstract][Full Text] [Related]
14. N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists.
Elliott JM; Carling RW; Chambers M; Chicchi GG; Hutson PH; Jones AB; MacLeod A; Marwood R; Meneses-Lorente G; Mezzogori E; Murray F; Rigby M; Royo I; Russell MG; Sohal B; Tsao KL; Williams B
Bioorg Med Chem Lett; 2006 Nov; 16(22):5748-51. PubMed ID: 16950620
[TBL] [Abstract][Full Text] [Related]
15. Identification of a new series of non-peptidic NK3 receptor antagonists.
Juhl K; Hansen T; Kehler J; Khanzhin NA; Nørgaard MB; Ruhland T; Larsen DB; Jensen KG; Steiniger-Brach B; Nielsen SM; Simonsen KB
Bioorg Med Chem Lett; 2011 Mar; 21(5):1498-501. PubMed ID: 21292483
[TBL] [Abstract][Full Text] [Related]
16. Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists.
Blaney FE; Raveglia LF; Artico M; Cavagnera S; Dartois C; Farina C; Grugni M; Gagliardi S; Luttmann MA; Martinelli M; Nadler GM; Parini C; Petrillo P; Sarau HM; Scheideler MA; Hay DW; Giardina GA
J Med Chem; 2001 May; 44(11):1675-89. PubMed ID: 11356103
[TBL] [Abstract][Full Text] [Related]
17. The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils.
Nordquist RE; Durkin S; Jacquet A; Spooren W
Eur J Pharmacol; 2008 Dec; 600(1-3):87-92. PubMed ID: 18930726
[TBL] [Abstract][Full Text] [Related]
18. Use of the beta-imager for rapid ex vivo autoradiography exemplified with central nervous system penetrating neurokinin 3 antagonists.
Langlois X; te Riele P; Wintmolders C; Leysen JE; Jurzak M
J Pharmacol Exp Ther; 2001 Nov; 299(2):712-7. PubMed ID: 11602685
[TBL] [Abstract][Full Text] [Related]
19. Effects of the peripherally acting NK receptor antagonist, SB-235375, on intestinal and somatic nociceptive responses and on intestinal motility in anaesthetized rats.
Shafton AD; Bogeski G; Kitchener PD; Lewis VA; Sanger GJ; Furness JB
Neurogastroenterol Motil; 2004 Apr; 16(2):223-31. PubMed ID: 15086876
[TBL] [Abstract][Full Text] [Related]
20. The NK1 receptor antagonist NKP608 lacks anxiolytic-like activity in Swiss-Webster mice exposed to the elevated plus-maze.
Rodgers RJ; Gentsch C; Hoyer D; Bryant E; Green AJ; Kolokotroni KZ; Martin JL
Behav Brain Res; 2004 Sep; 154(1):183-92. PubMed ID: 15302124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
